ID: ALA1098308

Max Phase: Preclinical

Molecular Formula: C25H23N5O2

Molecular Weight: 425.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(CN1CCCCC1)Nc1ccc2nc3c4[nH]c5ccccc5c4ccn3c(=O)c2c1

Standard InChI:  InChI=1S/C25H23N5O2/c31-22(15-29-11-4-1-5-12-29)26-16-8-9-21-19(14-16)25(32)30-13-10-18-17-6-2-3-7-20(17)27-23(18)24(30)28-21/h2-3,6-10,13-14,27H,1,4-5,11-12,15H2,(H,26,31)

Standard InChI Key:  WLAAJJZNAFKAMK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 425.49

Molecular Weight (Monoisotopic): 425.1852

AlogP: 3.91

#Rotatable Bonds: 3

Polar Surface Area: 82.50

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.03

CX Basic pKa: 7.05

CX LogP: 3.13

CX LogD: 2.97

Aromatic Rings: 5

Heavy Atoms: 32

QED Weighted: 0.43

Np Likeness Score: -1.24

References

1. Wang B, Mai YC, Li Y, Hou JQ, Huang SL, Ou TM, Tan JH, An LK, Li D, Gu LQ, Huang ZS..  (2010)  Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors.,  45  (4): [PMID:20079560] [10.1016/j.ejmech.2009.12.044]

2. He Y, Yao PF, Chen SB, Huang ZH, Huang SL, Tan JH, Li D, Gu LQ, Huang ZS..  (2013)  Synthesis and evaluation of 7,8-dehydrorutaecarpine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.,  63  [PMID:23501115] [10.1016/j.ejmech.2013.02.014]

3. Beato A, Gori A, Boucherle B, Peuchmaur M, Haudecoeur R..  (2021)  β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.,  64  (3.0): [PMID:33528252] [10.1021/acs.jmedchem.0c01887]

Source

Source(1):

• Scientific Literature